Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial

RIY Lieverse, EJ Van Limbergen, CJG Oberije, EGC Troost, SR Hadrup, AMA Dingemans, LEL Hendriks, F Eckert, C Hiley, C Dooms, Y Lievens, M de Jong, J Bussink, X Geets, V Valentini, G Elia, D Neri, C Billiet, A Abdollahi, D Du PasquierP Boisselier, A Yaromina, D De Ruysscher, LJ Dubois, P Lambin

Research output: Contribution to journalArticleAcademicpeer-review

31 Citations (Scopus)
12 Downloads (Pure)
Original languageEnglish
JournalBMC Cancer
Issue number1
Publication statusPublished - 2020

Research programs

  • EMC MM-04-42-02

Cite this